 It is thought that dysfunction of the neurotransmitter noradrenaline can result in a range of psychiatric disorders. However, the targeting of treatments for such disorders have been overshadowed by the availability and global attention of the selective serotonin reuptake inhibitors (SSRI’s). In spite of this mass attention and notoriety these SSRI’s have NOT demonstrated superior efficacy in major depression. The current popularity of the SSRIs (Seroxat, Prozac) for the treatment of depression should not hide the fact that noradrenaline also influences mood. Perhaps this is because the noradrenergic system in the brain appears to have a vital role in neurotransmitter organization. The importance of noradrenaline in depression is demonstrated by its functional role in vigilance, social interaction, a sense of worth and drive. Reboxetine (Edronax, Davedax) is the first truly selective noradrenaline reuptake inhibitor (NRI) and has been shown in clinical studies to be an effective and safe antidepressant. NRI’s such as Reboxetine thus seem to be at least as effective as the SSRI’s. It has been suggested that SSRI’s and NRI’s work against depression from two different pathways or angles. There is a feeling that NRI’s may be more effective than SSRI’s in severe depression. Reboxetine may also provide a better quality of the remission. Obviously there are many different types of depression and one drug can work well with a certain individual and not be effective in another. The clinical trials are both copious and continuous in this area of neurological medicine. Reboxetine must be taken for up to three to four weeks before benefits of treatment may appear. Always consult your medical professional before commencement of administration. Approved Uses © IAS Ltd. | 
